Advanced Search

Journal of Traditional Chinese Medicine >

2023 , Vol. 43 >Issue 6: 1168 - 1175

DOI: https://doi.org/10.19852/j.cnki.jtcm.20230814.002

Research Articles

Jianpi Qutan Fang (健脾祛痰方) induces anti-atherosclerosis and ameliorates endothelial cell injury in high-fat diet rats via an anti-inflammatory and inhibiting Janus kinase/signal transducer and activator of transcription signaling pathway

  • Yue LIU ,
  • Fan ZHANG ,
  • Xiaomeng HAN ,
  • Ningyang XU ,
  • Yu ZHAO ,
  • Qige WANG ,
  • Jianan WANG ,
  • Bingjiu LU ,
  • Yan Zhang
Expand
  • 1 Studio of Prestigious Chinese physician Zhang Yan, Affiliated hospital, Liaoning University of Traditional Chinese Medicine, Shenyang 110000, China
    2 Liaoning University of Traditional Chinese Medicine, Shenyang 110000, China
    3 Department of Infectious Disease, Affiliated hospital, Liaoning University of Traditional Chinese Medicine, Shenyang 110000, China
    4 Studio of Prestigious Chinese physician Zhang Yan, Department of Cardiopulmonary Rehabilitation, Affiliated hospital, Liaoning University of Traditional Chinese Medicine, Shenyang 110000, China

Received date: 2022-06-12

  Accepted date: 2022-10-22

  Online published: 2023-08-14

Supported by

Explore the Regulatory Mechanism of Coronary Endothelial Immune Inflammation Mediated by MicroRNA155-SOCS1 Axis in Bama Pigs based on “Xin Shou Qi Yu Pi”(81703970);Study on the Therapeutic Mechanism and Rule of Treating Angina Pectoris based on “Cong Pi Lun Zhi”(2013CB531704)

Fold

Abstract

OBJECTIVE: To investiage the possible mechanism underlying the effect of the Jianpi Qutan Fang (健脾祛痰方, JPQT) on Atherosclerosis (AS) which is the main pathological process of most cardiovascular diseases that affect millions of adults worldwide.
METHODS: In the present study, rats were fed with a high-fat-diet (HFD) with vitamin D3 for 16 weeks and were orally administered atorvastatin treatment and different doses of JPQT. Histopathological changes and ultrastructural changes in the aorta were evaluated through hematoxylin-eosin staining and transmission electron microscopy (TEM), respectively. Suppressor of cytokine signaling 1 (SOCS1)/Janus kinase 1 (JAK1)/ signal transducer and activator of transcription 1 (STAT1) signaling pathways were detected through Western blotting.
RESULTS: JPQT treatment decreased the lipid levels of triglyceride, low-density lipoprotein, and cholesterol, the inflammatory cytokine levels of interleukin 1 beta (IL-1β), IL-6 and IL-8 in rat serum, but increased high-density lipoprotein and IL-10 serum levels. JPQT treatment ameliorated pathological changes in the aorta of AS model rats. Moreover, JPQT upregulated SOCS1 protein expression and down-regulated phosphorylated protein expression levels of p-JAK1 and p-STAT1.
CONCLUSION: These results suggest that JPQT induces anti-atherosclerosis effects through anti-inflammatory and inhibiting JAK/STAT signaling pathways in HFD fed rats.

Key words： anti-inflammatory agents; Janus kinases; STAT transcription factors; signal transduction; diet, high-fat; antiatherosclerosis; Jianpi Qutan Fang

Cite this article

Yue LIU , Fan ZHANG , Xiaomeng HAN , Ningyang XU , Yu ZHAO , Qige WANG , Jianan WANG , Bingjiu LU , Yan Zhang . Jianpi Qutan Fang (健脾祛痰方) induces anti-atherosclerosis and ameliorates endothelial cell injury in high-fat diet rats via an anti-inflammatory and inhibiting Janus kinase/signal transducer and activator of transcription signaling pathway[J]. Journal of Traditional Chinese Medicine, 2023 , 43(6) : 1168 -1175 . DOI: 10.19852/j.cnki.jtcm.20230814.002

References

1. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 2018; 137: e67-492.
2. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 2017; 135: e146-603.
3. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000.
4. Zhao XX, Liu J, Zhao H, et al. The effect of cardiovascular risk factors on the carotid intima-media thickness in an old-aged cohort with hypertension: a longitudinal evolution with 4-year follow-up of a random clinical trial. Clin Exp Hypertens 2019; 41: 49-57.
5. Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag 2016; 12: 171-83.
6. Poznyak A, Grechko AV, Poggio P, et al. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci 2020; 21: 1835.
7. Nimai C Chandra. Atherosclerosis and carcinoma: two facets of dysfunctional cholesterol homeostasis. J Biochem Mol Toxicol 2020; 34: e22595.
8. Meurer L, Cohen SM. Drug-induced liver injury from statins. Clin Liver Dis 2020; 24: 107-19.
9. Vinci P, Panizon E, Tosoni LM, et al. Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int J Mol Sci 2021; 22: 11687.
10. Wu PS (Wei dynasty), Sun XY (Qing dynasty), Feng MY (Qing dynasty. Shen Nong Ben Cao Jing. Beijing: People's Medical Publishing House, 1984: 27.
11. Wang Y, Liu L, Ma Y, et al. Chemical discrimination of Astragalus mongholicus and Astragalus membranaceus based on metabolomics using UHPLC-ESI-Q-TOF-MS/MS Approach. Molecules 2019; 24: 4064.
12. Zhu Z, Li J, Zhang X. Astragaloside Ⅳ protects against oxidized low-density lipoprotein (ox-LDL)-induced endothelial cell injury by reducing oxidative stress and inflammation. Med Sci Monit 2019; 25: 2132-40.
13. Yang Y, Pei K, Zhang Q, et al. Salvianolic acid B ameliorates atherosclerosis via inhibiting YAP/TAZ/JNK signaling pathway in endothelial cells and pericytes. Biochim Biophys Acta Mol Cell Biol Lipids 2020; 1865: 158779.
14. Wang YL, Zhang Q, Yin SJ, et al. Screening of blood-activating active components from Danshen-Honghua herbal pair by spectrum-effect relationship analysis. Phytomedicine 2019; 54: 149-58.
15. Li ZM, Xu SW, Liu PQ. Salvia miltiorrhiza Burge (Danshen): a golden herbal medicine in cardiovascular therapeutics. Acta Pharmacol Sin 2018; 39: 802-24.
16. Aguilar-Ballester M, Herrero-Cervera A, Vinué á, Martínez-Hervás S, González-Navarro H. Impact of cholesterol metabolism in immune cell function and atherosclerosis. Nutrients 2020; 12: 2021.
17. Wojda A, Janczy A, Ma?gorzewicz S. Mediterranean, vegetarian and vegan diets as practical outtakes of EAS and ACC/AHA recommendations for lowering lipid profile. Acta Biochim Pol 2021; 68: 41-8.
18. Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. Circulation 2019;140: 992-1003.
19. Xu Y, Li F, Zhao X, et al. Methionine sulfoxide reductase a attenuates atherosclerosis via repairing dysfunctional HDL in scavenger receptor class B type I deficient mice. FASEB J 2020; 34: 3805-19.
20. Pownall HJ, Rosales C, Gillard BK, Gotto AM Jr. High-density lipoproteins, reverse cholesterol transport and atherogenesis. Nat Rev Cardiol 2021; 18: 712-23.
21. Bonaventura A, Montecucco F, Dallegri F, et al. Novel findings in neutrophil biology and their impact on cardiovascular disease. Cardiovasc Res 2019; 115: 1266-85.
22. Persson J, Nilsson J, Lindholm MW. Interleukin-1beta and tumour necrosis factor-alpha impede neutral lipid turnover in macrophage-derived foam cells. BMC Immunol 2008; 9: 70.
23. Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev 2014; 22: 147-51.
24. Zhang L, Li HY, Li H, et al. Lipopolysaccharide activated phosphatidylcholine -specific phospholipase C and induced IL-8 and MCP-1 production in vascular endothelial cells. J Cell Physiol 2011;226: 1694-701.
25. Kamari Y, Shaish A, Shemesh S, et al. Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1α. Biochem Biophys Res Commun 2011; 405: 197-203.
26. Kahraman S, Yilmaz R, Arici M, et al. IL-10 genotype predicts serum levels of adhesion molecules, inflammation and athero-sclerosis in hemodialysis patients. J Nephrol 2006; 19: 50-6.
27. Yu CR, Mahdi RR, Oh HM, et al. Suppressor of cytokine signaling-1 (SOCS1) inhibits lymphocyte recruitment into the retina and protects SOCS1 transgenic rats and mice from ocular inflammation. Invest Ophthalmol Vis Sci 2011; 52: 6978-86.
28. Baldini C, Moriconi FR, Galimberti S, Libby P, De Caterina R. The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. Eur Heart J 2021;4 2: 4389-400.
Options
Outlines

/

〈 〉